Researchers Develop SARS-CoV-2 Neutralizing Antibody that Could Cure as Well as Prevent COVID-19
|
By HospiMedica International staff writers Posted on 21 May 2020 |
|
Image: Sunney Xie (in the middle) and some members of his team (Photo courtesy of Peking University)
A team of Chinese researchers have successfully identified multiple highly potent neutralizing antibodies against the novel coronavirus SARS-CoV-2 from convalescent plasma by using high-throughput single-cell sequencing.
The new results of animal studies carried out by researchers at Peking University {(PKU) Beijing, China} showed that their neutralizing antibody provides a potential cure for COVID-19 as well as means for short-term prevention, making a major milestone in the fight against the pandemic.
The researchers collected blood samples from over 60 convalescent patients, among which 14 highly potent neutralizing antibodies were selected from 8,558 antigen-binding IgG1+ clonotypes. Their most potent antibody, BD-368-2, exhibited an IC50 of 8pM and 100pM against pseudotyped and authentic SARS-CoV-2. The in vivo antiviral experiment of neutralizing antibodies using hACE2 transgenic mice model showed that BD-368-2 antibody could provide strong therapeutic efficacy and prophylactic protection against SARS-CoV-2: When the BD-368-2 antibody was injected into infected mice, virus load was decreased by ~ 2400 times; when uninfected mice were injected with BD-368-2, they were protected from the virus infection.
In addition, the researchers also obtained the 3.8Å Cryo-EM structure of a neutralizing antibody in complex with the Spike-ectodomain trimer. It revealed the antibody’s epitope overlaps with the ACE2 binding-site, which provides the structural basis of neutralization. Moreover, they showed that SARS-CoV-2 neutralizing antibodies could be selected with high efficiency based on similarities of their predicted structures to those of SARS-CoV neutralizing antibodies, hence greatly expediting the screening process. The potent neutralizing antibody could be used to develop drugs for both therapeutic intervention and prophylactic protection against SARS-CoV-2. Clinical trials are underway, and the researchers are confident of finding a cure.
“If the COVID-19 epidemic reappears in the winter, our neutralizing antibody might be available by that time,” said Sunney Xie, Director of Beijing Advanced Innovation Center for Genomics at PKU.
Related Links:
Peking University
The new results of animal studies carried out by researchers at Peking University {(PKU) Beijing, China} showed that their neutralizing antibody provides a potential cure for COVID-19 as well as means for short-term prevention, making a major milestone in the fight against the pandemic.
The researchers collected blood samples from over 60 convalescent patients, among which 14 highly potent neutralizing antibodies were selected from 8,558 antigen-binding IgG1+ clonotypes. Their most potent antibody, BD-368-2, exhibited an IC50 of 8pM and 100pM against pseudotyped and authentic SARS-CoV-2. The in vivo antiviral experiment of neutralizing antibodies using hACE2 transgenic mice model showed that BD-368-2 antibody could provide strong therapeutic efficacy and prophylactic protection against SARS-CoV-2: When the BD-368-2 antibody was injected into infected mice, virus load was decreased by ~ 2400 times; when uninfected mice were injected with BD-368-2, they were protected from the virus infection.
In addition, the researchers also obtained the 3.8Å Cryo-EM structure of a neutralizing antibody in complex with the Spike-ectodomain trimer. It revealed the antibody’s epitope overlaps with the ACE2 binding-site, which provides the structural basis of neutralization. Moreover, they showed that SARS-CoV-2 neutralizing antibodies could be selected with high efficiency based on similarities of their predicted structures to those of SARS-CoV neutralizing antibodies, hence greatly expediting the screening process. The potent neutralizing antibody could be used to develop drugs for both therapeutic intervention and prophylactic protection against SARS-CoV-2. Clinical trials are underway, and the researchers are confident of finding a cure.
“If the COVID-19 epidemic reappears in the winter, our neutralizing antibody might be available by that time,” said Sunney Xie, Director of Beijing Advanced Innovation Center for Genomics at PKU.
Related Links:
Peking University
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Hybrid Arch Device
Neo EDE
New
Gas Analyzer
GE SAM
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Critical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
